Reportlinker Adds Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market

NEW YORK, Oct. 12 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market

http://www.reportlinker.com/p0312076/Hepatitis-Therapeutics-Market-to-2016---Strong-Hepatitis-C-Pipeline-and-Cost-Effective-Treatments-will-Drive-the-Global-Hepatitis-Market.html

Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market

Summary

GBI Research's pharmaceuticals report, "Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market", provides in-depth analysis of unmet needs, drivers and barriers that impact the global hepatitis therapeutics market. The report analyzes the markets for hepatitis therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research finds that the global hepatitis therapeutics market is one of the growing markets of the pharmaceutical business. Due to the approval of potential new drugs as well as combinational therapies, the hepatitis market will grow further. Launch of drugs with significant efficacy, safety and resistance profiles will fuel rapid uptake of drugs in near future. The limitations of current standard care therapy for hepatitis due to high incidence of adverse events, long duration of treatment, suboptimal patient compliance, lack of efficacy in specific genotypes has increased interest in developing novel products that can probably counter the unmet needs presented by the present market. However, the market sales growth is expected to slow down marginally due to the declining hepatitis incidence rates (use of vaccines), public awareness, and patent expiries of key therapeutics. Nevertheless, the global hepatitis market is still forecasted to grow at a compound annual growth rate (CAGR) of 3.1% between 2001 and 2009.

Scope

- Annualized market data for the hepatitis therapeutics market from 2001 to 2009, forecast forward to 2016.

- Analysis of the leading therapeutic segments, including hepatitis A, hepatitis B and hepatitis C.

- Analysis of the hepatitis therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.

- Market characterization of the hepatitis therapeutics market, including market size, annual cost of therapy and treatment usage patterns.

- Key drivers and barriers that have a significant impact on the market.

- Coverage of pipeline molecules in various phases of drug development.

- Competitive benchmarking of leading companies. The key companies studied in this report are Merck & Co, GlaxoSmithKline and F. Hoffman-La Roche.

- Key M&A activities, licensing agreements that have taken place between 2004 and mid-2010 in the global hepatitis therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to :

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.

- Develop key strategic initiatives by understanding the key focus areas of leading companies.

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 7

2 Global Hepatitis Therapeutics Market: Introduction 9

2.1 GBI Research Report Guidance 10

3 Global Hepatitis Therapeutics Market: Market Overview 11

3.1 Introduction 11

3.2 Revenue Forecasts for the Global Hepatitis Therapeutics Market 12

3.2.1 Sales Value 12

3.2.2 Treatment Usage Patterns 14

3.3 Hepatitis Market Drivers 19

3.3.1 Hepatitis C is a Growing Market with Strong Competition and a Promising Pipeline 19

3.3.2 Promising Developments in Hepatitis C Pipeline 19

3.3.3 Steady Increase in Prescription Population 20

3.4 Hepatitis Market Restraints 20

3.4.1 Hepatitis is Rarely Recognized During the Early Stages of the Disease Due to Lack of Symptoms during Acute Phase 20

3.4.2 Low Treatment Seeking Population 20

3.4.3 Loss of Exclusivity Protection in Hepatitis B Market 20

3.5 Generic Share in the Global Hepatitis Market 21

4 Global Hepatitis Market: Therapeutic Landscape 22

4.1 Introduction 22

4.1.1 Hepatitis A 22

4.1.2 Hepatitis B 22

4.2 Overview of Hepatitis A and B Vaccines Market 23

4.2.1 Sales Value 23

4.3 Hepatitis B Market 24

4.3.1 Introduction 24

4.3.2 Sales Value 25

4.3.3 Annual Cost of Therapy 26

4.3.4 Treatment Usage Patterns 27

4.3.5 Geographical Segmentation 32

4.4 Hepatitis C Market 34

4.4.1 Introduction 34

4.4.2 Sales Value 35

4.4.3 Annual Cost of Therapy 36

4.4.4 Treatment Usage Patterns 37

4.4.5 Geographical Segmentation 42

5 Global Hepatitis Market: Geographical Landscape 45

5.1 Geographical Break-up 45

5.2 The US 48

5.2.1 Sales Value 48

5.2.2 Annual Cost of Therapy 49

5.2.3 Treatment Usage Patterns 50

5.3 Top Five Countries in Europe 55

5.3.1 Sales Value 55

5.3.2 Annual Cost of Therapy 56

5.3.3 Treatment Usage Patterns 57

5.4 Japan 62

5.4.1 Sales Value 62

5.4.2 Annual Cost of Therapy 63

5.4.3 Treatment Usage Patterns 64

6 Global Hepatitis Vaccines and Therapeutics Market: Pipeline Analysis 69

6.1 Introduction 69

6.1.1 Research and Development Pipeline – Hepatitis B Therapeutics 71

6.1.2 Research and Development Pipeline – Hepatitis C Therapeutics 72

6.2 Profiles of Key Late-Stage Vaccines in the Hepatitis A & B Market 73

6.2.1 Heplisav 73

6.3 Molecule Profile for Promising Therapeutics for Hepatitis B under Clinical Development 74

6.3.1 Entecavir + Adefovir combination therapy 74

6.3.2 Truvada (Tenofovir plus Emtricitabine combination therapy) 74

6.4 Molecule Profile for Promising Therapeutics for Hepatitis C under Clinical Development 75

6.4.1 Boceprevir (SCH 503034, narlaprevir) 75

6.4.2 Tenofovir + Emtricitabine Combination therapy 76

6.4.3 Zalbin (albinterferon alfa-2b, Joulferon) 76

6.4.4 Telaprevir (VX 905) 77

6.4.5 RG 7128 79

7 Global Hepatitis Vaccines & Therapeutics Market: Competitive Landscape 81

7.1 Market Share Analysis: Hepatitis 81

7.2 Competitive Profiling 82

7.2.1 Merck & Co., Inc. 82

7.2.2 F. Hoffmann-La Roche Ltd. 85

7.2.3 GlaxoSmithKline plc 87

8 Global Hepatitis Market: Strategic Consolidations 89

8.1 Mergers and Acquisitions 89

8.1.1 Overview 89

8.1.2 Summary of M&A Deals (2009-2010) 90

8.2 R&D Licensing Agreements 91

8.2.1 Summary of Licensing Deals (2009-2010) 91

9 Global Hepatitis Market: Appendix 96

9.1 Market Definitions 96

9.2 Abbreviations 96

9.3 Research Methodology 97

9.4 Research Methodology 97

9.4.1 Coverage 97

9.4.2 Secondary Research 97

9.4.3 Primary Research 98

9.4.4 Forecasts 98

9.4.5 Expert Panel Validation 100

9.5 Contact Us 101

9.6 Disclaimer 101

1.1 List of Tables

Table 1: Hepatitis Therapeutics Market, Global, Sales Value ($m), 2001–2009 12

Table 2: Hepatitis Therapeutics Market, Global, Sales Value ($m), 2009–2016 12

Table 3: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2001–2009 13

Table 4: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2009–2016 13

Table 5: Hepatitis Therapeutics Market, Global, Treatment Usage Patterns, 2001–2009 15

Table 6: Hepatitis Therapeutics Market, Global, Treatment Usage Patterns, 2009–2016 15

Table 7: Hepatitis Therapeutics Market, Global, Hepatitis A and B Vaccines Sales Value ($m), 2001–2009 23

Table 8: Hepatitis Therapeutics Market, Global, Hepatitis A and B Vaccines Sales Value ($m), 2009–2016 23

Table 9: Hepatitis Therapeutics Market, Global, Hepatitis B Sales Value ($m), 2001–2009 25

Table 10: Hepatitis Therapeutics Market, Global, Hepatitis B Sales Value ($m), 2009–2016 25

Table 11: Hepatitis Therapeutics Market, Global, Hepatitis B Annual Cost of Therapy ($), 2001–2009 26

Table 12: Hepatitis Therapeutics Market, Global, Hepatitis B Annual Cost of Therapy ($), 2009–2016 26

Table 13: Hepatitis Therapeutics Market, Global, Hepatitis B Treatment Usage Patterns ('000), 2001–2009 27

Table 14: Hepatitis Therapeutics Market, Global, Hepatitis B Treatment Usage Patterns ('000), 2009–2016 28

Table 15: Hepatitis Therapeutics Market, Global, Hepatitis B Market Geographical Segmentation ($m), 2001–2009 33

Table 16: Hepatitis Therapeutics Market, Global, Hepatitis B Market Geographical Segmentation ($m), 2009–2016 33

Table 17: Hepatitis Therapeutics Market, Global, Hepatitis C Sales Value ($m), 2001–2009 35

Table 18: Hepatitis Therapeutics Market, Global, Hepatitis C Sales Value ($m), 2009–2016 35

Table 19: Hepatitis Therapeutics Market, Global, Hepatitis C Annual Cost of Therapy ($), 2001–2009 36

Table 20: Hepatitis Therapeutics Market, Global, Hepatitis C Annual Cost of Therapy ($), 2009–2016 36

Table 21: Hepatitis Therapeutics Market, Global, Hepatitis C Treatment Usage Patterns, 2001–2009 37

Table 22: Hepatitis Therapeutics Market, Global, Hepatitis C Treatment Usage Patterns, 2009–2016 38

Table 23: Hepatitis Therapeutics Market, Global, Hepatitis C Geographical Market Segmentation, 2001–2009 43

Table 24: Hepatitis Therapeutics Market, Global, Hepatitis C Geographical Market Segmentation, 2009–2016 43

Table 25: Hepatitis Therapeutics Market, Global, Sales Value by Geography ($m), 2001–2009 46

Table 26: Hepatitis Therapeutics Market, Global, Sales Value by Geography ($m), 2009–2016 46

Table 27: Hepatitis Therapeutics Market, US, Sales Value ($m), 2001–2009 48

Table 28: Hepatitis Therapeutics Market, US, Sales Value ($m), 2009–2016 48

Table 29: Hepatitis Therapeutics Market, US, Annual Cost of Therapy ($), 2001–2009 49

Table 30: Hepatitis Therapeutics Market, US, Annual Cost of Therapy ($), 2009–2016 49

Table 31: Hepatitis Therapeutics Market, US, Treatment Usage Patterns ('000), 2001–2009 50

Table 32: Hepatitis Therapeutics Market, US, Treatment Usage Patterns ('000), 2009–2016 51

Table 33: Hepatitis Therapeutics Market, Top Five Countries in Europe, Sales Value ($m), 2001–2009 55

Table 34: Hepatitis Therapeutics Market, Top Five Countries in Europe, Sales Value ($m), 2009–2016 55

Table 35: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2001–2009 56

Table 36: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2009–2016 56

Table 37: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern ('000), 2001–2009 57

Table 38: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern (000's), 2009–2016 58

Table 39: Hepatitis Therapeutics Market, Japan, Sales Value ($m), 2001–2009 62

Table 40: Hepatitis Therapeutics Market, Japan, Sales Value ($m), 2009–2016 62

Table 41: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001–2009 63

Table 42: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2009–2016 63

Table 43: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern ('000), 2001–2009 64

Table 44: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern ('000), 2009–2016 65

Table 45: Final Prove 3 SVR Results for Telaprevir, HCV 78

1.2 List of Figures

Figure 1: Hepatitis Market, Global, Drivers and Restraints, 2009 11

Figure 2: Hepatitis Therapeutics Market, Global, Sales Value ($m), 2001–2016 12

Figure 3: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2001–2016 13

Figure 4: Hepatitis Therapeutics Market, Global, Therapeutic Usage Patterns, 2001–2016 14

Figure 5: Hepatitis Therapeutics Market, Global, Diseases Population, 2001–2016 16

Figure 6: Hepatitis Therapeutics Market, Global, Treatment Seeking Population, 2001–2016 17

Figure 7: Hepatitis Therapeutics Market, Global, Diagnosed Population, 2001–2016 18

Figure 8: Hepatitis Therapeutics Market, Global, Prescription Population, 2001–2016 19

Figure 9: Hepatitis B and Hepatitis C Therapeutic Market, Global, Branded and Generic Drugs (%), 2009 21

Figure 10: Hepatitis Therapeutics Market, Global, Hepatitis A and B Vaccines Sales Value ($m), 2001–2016 23

Figure 11: Hepatitis Therapeutics Market, Global, Hepatitis B-Genotypes Based on Geographic Origins 24

Figure 12: Hepatitis Therapeutics Market, Global, Hepatitis B Sales Value ($m), 2001–2016 25

Figure 13: Hepatitis Therapeutics Market, Global, Hepatitis B Annual Cost of Therapy ($), 2001–2016 26

Figure 14: Hepatitis Market, Global, Hepatitis B Treatment Usage Patterns, 2001–2016 27

Figure 15: Hepatitis Market, Global, Hepatitis B Diseased Population, 2001–2016 28

Figure 16: Hepatitis Therapeutics Market, Global, Hepatitis B Treatment Seeking Population, 2001–2016 29

Figure 17: Hepatitis Market, Global, Hepatitis B Diagnosis Population, 2001–2016 30

Figure 18: Hepatitis Therapeutics Market, Global, Hepatitis B Prescription Population, 2001–2016 31

Figure 19: Hepatitis Therapeutics Market, Global, Hepatitis B Market Segmentation by Geography (%), 2009 and 2016 32

Figure 20: Hepatitis Therapeutics Market, Global, Hepatitis B Market Geographical Segmentation ($m), 2001–2016 32

Figure 21: Hepatitis Therapeutics Market, Global, Hepatitis B Market, Geography Benchmarking, 2009 34

Figure 22: Hepatitis Therapeutics Market, Global, Hepatitis C Sales Value ($m), 2001–2016 35

Figure 23: Hepatitis Therapeutics Market, Global, Hepatitis C Annual Cost of Therapy ($), 2001–2016 36

Figure 24: Hepatitis Therapeutics Market, Global, Hepatitis C Treatment Usage Patterns, 2001–2016 37

Figure 25: Hepatitis Therapeutics Market, Global, Hepatitis C Diseased Population, 2001–2016 38

Figure 26: Hepatitis Therapeutics Market, Global, Hepatitis C Treatment Seeking Population, 2001–2016 39

Figure 27: Hepatitis Therapeutics Market, Global, Hepatitis C Diagnosis Population, 2001–2016 40

Figure 28: Hepatitis Therapeutics Market, Global, Hepatitis C Prescription Population, 2001–2016 41

Figure 29: Hepatitis Therapeutics Market, Global, Hepatitis C Market Segmentation by Geography (%), 2009 and 2016 42

Figure 30: Hepatitis Therapeutics Market, Global, Hepatitis C Geographical Market Segmentation ($m), 2001–2016 42

Figure 31: Hepatitis Therapeutics Market, Global, Hepatitis C Market, Geography Benchmarking, 2009 44

Figure 32: Hepatitis Therapeutics Market, Global, Market Share by Geography (%), 2009 and 2016 45

Figure 33: Hepatitis Therapeutics Market, Global, Sales Value by Geography ($m), 2001–2016 46

Figure 34: Hepatitis Therapeutics Market, Global, Geography Benchmarking, 2009 and 2016 47

Figure 35: Hepatitis Therapeutics Market, US, Sales Value ($m), 2001–2016 48

Figure 36: Hepatitis Therapeutics Market, US, Annual Cost of Therapy ($), 2001–2016 49

Figure 37: Hepatitis Therapeutics Market, US, Treatment Usage Patterns, 2001–2016 50

Figure 38: Hepatitis Therapeutics Market, US, Diseased Population, 2001–2016 51

Figure 39: Hepatitis Therapeutics Market, US, Treatment Seeking Population, 2001–2016 52

Figure 40: Hepatitis Therapeutics Market, US, Diagnosed Population, 2001–2016 53

Figure 41: Hepatitis Therapeutics Market, US, Prescription Population, 2001–2016 54

Figure 42: Hepatitis Therapeutics Market, Top Five Countries in Europe, Sales Value ($m), 2001–2016 55

Figure 43: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2001–2016 56

Figure 44: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Patterns, 2001–2016 57

Figure 45: Hepatitis Therapeutics Market, Top Five Countries in Europe, Diseased Population, 2001–2016 58

Figure 46: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Seeking Population, 2001–2016 59

Figure 47: Hepatitis Therapeutics Market, Top Five Countries in Europe, Diagnosed Population, 2001–2016 60

Figure 48: Hepatitis Therapeutics Market, Top Five Countries in Europe, Prescription Population, 2001–2016 61

Figure 49: Hepatitis Therapeutics Market, Japan, Sales Value ($m), 2001–2016 62

Figure 50: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001–2016 63

Figure 51: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern, 2001–2016 64

Figure 52: Hepatitis Therapeutics Market, Japan, Diseased Population, 2001–2016 65

Figure 53: Hepatitis Therapeutics Market, Japan, Treatment Seeking Population, 2001–2016 66

Figure 54: Hepatitis Therapeutics Market, Japan, Diagnosed Population, 2001–2016 67

Figure 55: Hepatitis Therapeutics Market, Japan, Prescription Population, 2001–2016 68

Figure 56: Hepatitis Therapeutics Market, Global, R&D Pipeline by Indication (%), March 2010 69

Figure 57: Hepatitis Therapeutics Market, Global, R&D Pipeline by Phase (%), March 2010 70

Figure 58: Hepatitis Therapeutics Market, Global, R&D Pipeline by Phase in Hepatitis B vaccines Market (%), March 2010 71

Figure 59: Hepatitis Therapeutics Market, Global, R&D Pipeline by Phase in Hepatitis C vaccines Market (%), March 2010 72

Figure 60: Hepatitis B and Hepatitis C Therapeutics Markets, Global, Market Share of Top Manufacturers (%), 2010 81

Figure 61: Hepatitis Vaccine Market, Global, Revenue of Top Players (%), 2010 82

Figure 62: Merck & Co., Inc., SWOT Analysis, 2010 83

Figure 63: F. Hoffmann-La Roche Ltd., SWOT Analysis, 2010 85

Figure 64: GlaxoSmithKline plc, SWOT Analysis, 2010 87

Figure 65: Hepatitis Therapeutics Market, Global, M&A Deals by Geography, (%), 2010 89

Figure 66: Hepatitis Therapeutics Health Market, Global, M&A Deals by Type, (%), 2010 90

Figure 67: Hepatitis Therapeutics Market, Global, Major Licensing Agreements By Indication (%), 2010 91

Figure 68: GBI Research Market Forecasting Model 100

Companies mentioned

Merck & Co., Inc.

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline plc

To order this report:

Therapy Industry: Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market

Therapy Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker